|
| |
CeNeS Announces New Scientific Advisory Board Friday 1st of April 2005 8:00
CeNeS Announces New Scientific Advisory Board
Cambridge, UK, 25 April 2005 - CeNeS Pharmaceuticals
plc (AIM: CEN) (“CeNeS” or “the Company”) today announced the appointment of a
new Scientific Advisory Board (SAB). The SAB will meet regularly to provide
CeNeS with scientific and clinical guidance for its research and development
activities.
The company has appointed Dr Ann Hayes, an independent industry consultant in
the CNS area, Professor David Brooks of the Division of Neuroscience, Imperial
College London, Dr Mick Serpell of the Department of Anaesthesia, University of
Glasgow, and Dr David Brown who has had a variety of research and executive
roles in the biopharmaceutical industry. Together they bring a range of
expertise in CNS disorders, drug discovery and development, and industry
expertise to CeNeS.
"We are delighted that the highest calibre scientists have decided to join our
SAB," said Neil Clark, CEO of CeNeS. “With their recognised knowledge of CNS
drug discovery and development and expertise in pain, anaesthesia and
Parkinson's disease, they will provide excellent support to our drug development
programmes".
Ann Hayes, who will chair the SAB, commented “CeNeS has a logical, lower-risk
approach to drug discovery and an exciting portfolio ranging from candidates at
the lead optimisation stage through to M6G which is in Phase III clinical trials
for post-operative pain. I am very pleased to be part of the impressive team of
advisors that has been assembled and look forward to contributing to the
progression of CeNeS’ programmes”.
ENDS
Notes to editors:
The CeNeS SAB members are as follows:
Ann Hayes Ph.D
Ann worked for 22 years for GlaxoWellcome specialising in the areas of CNS and
pain. She was a Director in Drug Discovery, with particular expertise in
determining long-term discovery strategy, in portfolio management and in
discovery project management. After leaving GSK in 2001, Ann set up a business
as an independent pharmaceutical consultant. In this capacity she has co-founded
two companies, Ionix Pharmaceuticals and TheraSci, which has since been bought
by CeNeS. Ann is a non-executive director of the biotechnology companies Ionix
and Curidium, a member of the Scientific Advisory Board for Biowisdom and has
also been non-executive director at TheraSci and Sirus (which was recently sold
to Arakis).
David J Brooks MD DSc FRCP FMed Sci
David Brooks is Hartnett Professor of Neurology and Head of the Department of
Sensorimotor Systems in the Division of Neuroscience, Faculty of Medicine,
Imperial College, London. He is also Head of the Neurology Group at the Medical
Research Council Clinical Sciences Centre, Hammersmith Hospital, London.
Additionally, he is Chief Medical Officer of Imanet, GE Healthcare PLC. David is
a member of the International Research Advisory Board of several organisations
including the Michael J. Fox Foundation for Parkinson's Disease Research and the
Medical Research Council Neuroscience and Mental Health board. David is on the
Editorial Boards of several journals. In 2001 he was elected a Fellow of the
Academy of Medical Science, UK. His research involves the use of positron
emission tomography and magnetic resonance imaging to study cerebral control of
movement and performance in therapeutic trials for Parkinson's, Huntington's,
and Alzheimer's diseases. To date, he has published over 250 reports in peer
reviewed journals, including Nature.
Mick Serpell, MB ChB, FSChP, ECFMG, FRCA
Mick Serpell graduated from Medical School at the University of Dundee in 1983.
He completed his training in Anaesthesia and Pain Management in Dundee,
Scotland, Orebro in Sweden and Dartmouth Hitchcock Medical Centre in New
Hampshire, USA. He took up his Consultant post in Glasgow in 1993 and became
Senior Lecturer at the University of Glasgow Department of Anaesthesia in 1999.
His research interests include pharmacological and regional analgesia management
of acute and chronic pain. He is particularly interested in the diagnosis and
early treatment of neuropathic pain. He leads the Clinical Trials Unit at the
Pain Clinic in Gartnavel. He has undertaken 24 commercial studies over the past
six years, and is on the Advisory Board of four commercial companies. He is
Chairman of the Research and Priority Programme for Pain & Acute Medicine for
the Glasgow Acute Hospital Trusts. Mick is Lead Clinician in Chronic Pain for
North Glasgow and Chairs the Neuropathic Pain Special Interest Group (British
Pain Society).
David Brown PhD, FRSC
David Brown has over 30 years experience in the pharmaceutical / biotechnology
industry both in research and in senior executive roles. From 1974-2002 he
served with four of the top 10 Pharma companies: Zeneca, Pfizer, Glaxo, and most
recently with F. Hoffman La-Roche as Global Head of Drug Discovery. In this role
he had responsibility for the output of clinical candidate drugs from
approximately 2000 scientists across Roche's five research sites. From 2002-2004
David was President and CEO of Cellzome AG, a biotechnology company
headquartered in Heidelberg, Germany. David has extensive experience of
pharmaceutical R&D. Whilst at Pfizer he was named co-inventor on the patent for
Viagra, a treatment for male impotence, and led the team that developed Viagra
through to proof of clinical efficacy in man. He also played a key role in the
discovery of Relpax, a treatment for migraine. David is now an independent
pharmaceutical consultant
About CeNeS Pharmaceuticals
CeNeS is a biopharmaceutical company specialising in the development and
commercialisation of drugs for pain control, sedation and other CNS disorders
such as Parkinson’s disease. The company is based in Cambridge, England. For
further information visit the CeNeS web site: www.cenes.com.
For further information please contact:
CeNeS Pharmaceuticals plc:
Alan Goodman/Neil Clark
Tel: +44 (0)1223 266466
Fax: +44 (0)1223 266467
Northbank Communications
Media Enquiries:
Rowan Minnion
Tel: +44 (0)20 7886 8154
Financial Enquiries:
Emma Palmer
Tel: +44 (0)20 7886 8159
Browse other news from this organisation: Cenes
Related Web-Links(If any, Generated Automatically)
Download PDF 
|
